Loading...
SESN logo

Sesen Bio, Inc.NasdaqCM:SESN Stock Report

Market Cap US$2.6b
Share Price
n/a
My Fair Value
n/a
1Y-7.1%
7D6.5%
1D
Portfolio Value
​
View

Sesen Bio, Inc.

NasdaqCM:SESN Stock Report

Market Cap: US$2.6b

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio (SESN) Stock Overview

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. More details

SESN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


SESN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Sesen Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sesen Bio
Historical stock prices
Current Share PriceUS$12.58
52 Week HighUS$19.30
52 Week LowUS$7.30
Beta0.83
1 Month Change8.32%
3 Month Change21.04%
1 Year Change-7.05%
3 Year Change-12.67%
5 Year Change-45.32%
Change since IPO-94.20%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 21

Sesen Bio and Carisma Therapeutics announce merger agreement

Sesen Bio (NASDAQ:SESN) and Carisma Therapeutics has entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and other serious disorders. The combined company expected to have ~$180M of cash, equivalents and marketable securities at close, including $30M from a concurrent financing by Carisma, which is expected to fund the combined company through 2024. Also, the cash runway of combined company expected to enable multiple clinical readouts across Carisma programs. The combined company is expected to operate under the name Carisma Therapeutics and trade on Nasdaq under the ticker symbol “CARM”.
Seeking Alpha • Aug 08

Sesen Bio GAAP EPS of -$0.16 misses by $0.03

Sesen Bio press release (NASDAQ:SESN): Q2 GAAP EPS of -$0.16 misses by $0.03. Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Cash, cash equivalents and marketable securities were $161.2 million as of June 30, 2022, compared to $151.1 million as of June 30, 2021. Shares -1.82% PM.
Seeking Alpha • Jul 27

Sesen Bio granted additional time period for regaining compliance

Nasdaq Listing Qualifications department notified Sesen Bio (NASDAQ:SESN) that it has been granted a second 180-day grace period, or until Jan.23, 2023 for regaining compliance with the minimum bid price requirement. In January, the company had received its non-compliance letter and was granted time until July 25, 2022, to regain compliance with the minimum bid price requirement. The stock will be transferred to the Nasdaq Capital Market effective July 28, 2022 and will continue to trade under the current symbol. Shares trading 2% down premarket
Seeking Alpha • Jul 18

Sesen Bio slips after decision to pause U.S. studies for lead asset

The shares of cancer-focused biotech Sesen Bio (NASDAQ:SESN) traded lower in the pre-market Monday after the company announced its decision to pause further development of its lead asset Vicineum in the U.S. Sesen (SESN) noted that after discussions with the FDA, the company reassessed the development path for Vicineum, including a Phase 3 trial for the treatment in non-muscle invasive bladder cancer (NMIBC). The decision to pause further studies allows the company to save cash as it explores potential strategic alternatives to maximize shareholder value, according to the management. Additionally, Sesen (SESN) expects to form a partnership for the further development of Vicineum. However, the company’s Chief Executive, Dr. Thomas Cannell, noted that the current commercial environment of NMIBC also led to its decision. “We have also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage,” he said. In Aug. 2021, the FDA declined to approve Vicineum for the treatment of BCG-unresponsive NMIBC.
Seeking Alpha • Jun 02

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives

SESN is a clinical-stage biopharma company working on the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). FDA declined to approve the company's flagship drug Vicineum. Subsequently, management has started a strategic review. SESN trades at $0.58/share vs $0.75/share of net cash.
Analysis Article • Apr 17

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 05

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Nov 24

Sesen Bio: Interesting Price Drop After CRL

Sesen received a CRL in August. Another trial will be needed. Sesen held a Type A meeting with the FDA on Oct. 29 on the CMC questions.
Seeking Alpha • Nov 17

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of the BLA. Ahead of the Type A meeting, the burden of proof will be on Sesen’s side to show the efficacy of Vicineum post-2017. Sesen Bio is gearing towards product commercialization with strategic hires into 2022. Study shows that high-prescribing urologists would use a treatment agent branded with Vicineum in more than 80% of the BCG-unresponsive NMIBC patients as opposed to 17% with Keytruda. Sesen Bio is able to fund its capital operations including R&D until 2023 when it is expected to begin commercialization of Vicineum.
Seeking Alpha • Aug 23

Sesen Bio: The Road Ahead

The current FDA environment is under heavy scrutiny with much uncertainty. Sesen Bio's lead drug, Vicineum, received a complete response letter from the Agency which put tremendous pressure on the stock. The company is eager to conduct a Type A meeting with the FDA to discuss the path ahead.
Analysis Article • Aug 12

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Investors in Sesen Bio, Inc. ( NASDAQ:SESN ) had a good week, as its shares rose 4.7% to close at US$4.04 following the...
Analysis Article • Feb 18

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Today is shaping up negative for Sesen Bio, Inc. ( NASDAQ:SESN ) shareholders, with the analysts delivering a...
Analysis Article • Jan 26

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Sesen Bio...
Analysis Article • Dec 21

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Sesen Bio, Inc.'s...

Shareholder Returns

SESNUS BiotechsUS Market
7D6.5%1.1%0.8%
1Y-7.1%27.5%24.2%

Return vs Industry: SESN underperformed the US Biotechs industry which returned 4.3% over the past year.

Return vs Market: SESN exceeded the US Market which returned -8.5% over the past year.

Price Volatility

Is SESN's price volatile compared to industry and market?
SESN volatility
SESN Average Weekly Movement9.4%
Biotechs Industry Average Movement10.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: SESN has not had significant price volatility in the past 3 months.

Volatility Over Time: SESN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200817Thomas Cannellsesenbio.com

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent.

Sesen Bio, Inc. Fundamentals Summary

How do Sesen Bio's earnings and revenue compare to its market cap?
SESN fundamental statistics
Market capUS$2.56b
Earnings (TTM)-US$19.88m
Revenue (TTM)US$40.00m
64.0x
P/S Ratio
-128.7x
P/E Ratio

Is SESN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SESN income statement (TTM)
RevenueUS$40.00m
Cost of RevenueUS$1.99m
Gross ProfitUS$38.02m
Other ExpensesUS$57.90m
Earnings-US$19.88m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.098
Gross Margin95.04%
Net Profit Margin-49.71%
Debt/Equity Ratio0%

How did SESN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/08 22:50
End of Day Share Price 2023/03/07 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sesen Bio, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.
Christopher HowertonJefferies LLC